It's heating up in the kitchen...
The FDA has now approved two biosimilars of Eylea, the first marketing approvals it has given for Eylea copy drugs.
Biocon Biologics' Yesafili (aflibercept-jbvf) and Samsung Bioepis and Biogen's Opuviz (aflibercept-yszy) carry interchangeable designations which allows them to be substituted with biosimilars without the need for a doctor's advice.
Both Yesafili and Opuviz are administered intravitreally as a 2 mg dose. Like Eylea, the biosimilars will be used to treat wet AMD, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.
In anticipation of the challenge from biosimilars, Regeneron has been focusing on its potentially longer duration 8 mg dose Eylea but this drug also faces pressure from rival drugs including Roche's less frequently administered 6mg dose Vabysmo.
US sales last year from the regular 2mg dose of Eylea were US$5.72 bn.
FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions | FDA
Regulatory tracker: FDA approves Eylea biosimilars from Biocon Biologics, Biogen | Fierce Pharma
US FDA approves two biosimilars for blockbuster eye drug Eylea | Reuters
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-52
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
34.5¢ |
Change
-0.005(1.43%) |
Mkt cap ! $376.5M |
Open | High | Low | Value | Volume |
36.0¢ | 36.5¢ | 34.5¢ | $232.4K | 666.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 906562 | 34.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.0¢ | 35109 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 906562 | 0.345 |
17 | 288482 | 0.340 |
9 | 831365 | 0.335 |
7 | 102505 | 0.330 |
5 | 188772 | 0.325 |
Price($) | Vol. | No. |
---|---|---|
0.350 | 35109 | 1 |
0.355 | 12440 | 1 |
0.360 | 12440 | 1 |
0.365 | 20718 | 2 |
0.370 | 174576 | 2 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online